統合失調症治療薬の世界市場（2025年～2032年）

世界の統合失調症治療薬の市場規模は、2024年に100億3,000万米ドルに達し、2032年には155億8,000万米ドルに達すると予測され、予測期間2024年～2032年のCAGRは5.7％で成長する見通しです。

統合失調症は、幻覚、妄想、異常な思考や行動を経験する深刻な精神疾患です。症状は10代後半から20代前半にかけて現れ始めます。統合失調症の症状は陽性と陰性に分類されます。陽性症状には幻覚、妄想的行動、異常な信念の形成などが含まれます。陰性症状には、社会的活動・言語出力・感情表現の低下などが含まれます。

統合失調症には治療法がなく、患者は生涯治療を受けなければなりません。最も一般的な治療法は、抗精神病薬などの処方薬、リハビリテーション、精神療法などです。

統合失調症市場は、罹患率の上昇と予想される製品承認によって牽引されると予測されます。

市場力学：

促進要因と抑制要因

統合失調症の有病率の上昇

統合失調症の有病率の上昇は、予測期間における市場成長の重要な促進要因です。世界的にメンタルヘルスに対する意識が高まり、統合失調症の診断率が大幅に上昇し、その結果、治療を選択する患者数が増加しています。世界保健機関（WHO）によると、世界中で2,400万人以上が統合失調症を患っており、精神病院に入院している患者の50％が統合失調症です。Environmental Research誌に掲載された調査によると、世界の統合失調症の発症率は1990年～2019年に37.23％上昇しています。罹患者総数は1990年に94万人、2019年には129万人でした。この研究では、急速な都市化、社会人口統計学的指標の改善が罹患率の上昇に大きく寄与していると結論付けています。

世界の大半の国は急速に成長しており、DataMの推計によれば、2030年の統合失調症罹患者数は145万人に達すると予想されています。このような罹患率の上昇に加え、先進的な治療に対する需要の高まりが、予測期間中の市場成長を大きく促進すると予想されます。

統合失調症治療薬の高コストが市場成長を抑制する可能性

統合失調症は長期の治療が必要な疾患です。ブランド名で販売されている新しい抗精神病薬は高価であり、低所得層の間ではその採用がしばしば疑問視されています。例えば、最近米国FDAに承認されたコベンファイ（キサノメリンと塩化トロスピウム）は、1ヵ月1,850米ドルで購入でき、年間では2万2,000米ドルです。これは、保険が適用されなかったり、部分的に適用されている患者には大きな経済的負担となります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 統合失調症の有病率の上昇
    • 先進的な治療法に対する需要の高まり
  • 抑制要因
    • 薬に伴う副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• 疫学
• 価格分析
• パイプライン分析
• 特許分析
• 規制分析

第6章 薬剤クラス別

• 定型抗精神病薬
• 非定型抗精神病薬
  • クエチアピン
  • アリピプラゾール
  • リスペリドン
  • ルラシドン
  • クロザピン
  • オランザピン
  • ブレクスピプラゾール
  • ルマテペロン
  • その他

第7章 投与経路別

• 経口
• 非経口

第8章 流通チャネル別

• 院内薬局
• 小売薬局
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Bristol-Myers Squibb Company
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 実績および予測の製品販売
    • 製品販売量
  • 財務概要
    • 企業収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Otsuka Pharmaceutical Co., Ltd.
• CHEPLAPHARM Arzneimittel GmbH
• Johnson & Johnson Services, Inc.
• Sumitomo Pharma Co., Ltd.
• Novartis AG
• Tasman Pharma, INC.
• Intra-Cellular Therapies, Inc.
• AbbVie Inc.
• Alkermes, Inc.
• Viatris Inc.
• Vanda Pharmaceuticals Inc.

第12章 付録

The global schizophrenia drugs market reached US$ 10.03 billion in 2024 and is expected to reach US$ 15.58 billion by 2032, growing at a CAGR of 5.7% during the forecast period 2024-2032.

Schizophrenia is a serious mental health condition in which the affected patient may experience hallucinations, delusions, abnormal thinking and behavior. The symptoms may start first appearing in a person during their early 20's or late teenage. The symptoms of schizophrenia were classified into positive and negative. The positive symptoms include hallucinations, paranoid behavior, development of abnormal beliefs, etc. The negative symptoms include reduced social activity, speech output, emotional expression, etc.

There is no cure for schizophrenia, and patients have to take lifetime treatment. The most common treatment includes prescription medicine such as antipsychotics, rehabilitation, and psychotherapy.

The market for schizophrenia is expected to be driven by the rising incidence and anticipated product approvals in the forecast period.

Market Dynamics: Drivers & Restraints

The rising prevalence of schizophrenia

The rising prevalence of schizophrenia is the significant driver for the market growth in the forecast period. Globally the rising awareness of mental health has significantly increased the diagnosis rate of schizophrenia and consequent patient population who are opting for treatments. As per the World Health Organization (WHO), more than 24 million people worldwide are suffering from schizophrenia, and 50% of the population in mental hospitals have schizophrenia. A study published in the Environmental Research journal has stated that the global incidence of schizophrenia has risen by 37.23% from 1990 to 2019. The total incidence cases were 0.94 million in 1990 and 1.29 million in 2019. The study concluded that the rapid urbanization, and improving sociodemographic index have significantly contributed to the rising incidence.

The majority of the countries worldwide are rapidly growing, and as per dataM estimates, the incidence cases of schizophrenia in 2030 are expected to reach 1.45 million. This rising incidence, combined with the growing demand for advanced treatments is expected to significantly propel the market growth in the forecast period.

The high cost of schizophrenia drugs may restrain the market growth.

Schizophrenia is a condition that requires prolonged/life-long treatment. The new antipsychotic drugs that are sold under brand names are expensive and their adoption is often questioned among low-income populations. For instance, cobenfy (xanomeline and trospium chloride) which was recently approved by the U.S. FDA is available for US$1,850 per month which is ~US$22,000 per year. This can create a significant economic burden on patients who lack insurance coverage and are on partial coverage.

Segment Analysis

The global schizophrenia drugs market is segmented based on drug class, route of administration, distribution channel, and region.

Atypical antipsychotics in the drug class segment are dominating the market.

Atypical antipsychotics (second-generation antipsychotics) are the drugs known to cause less extrapyramidal symptoms than typical antipsychotics (first-generation antipsychotics). Atypical antipsychotics act on serotonin, and norepinephrine receptors as well, in addition to their minimal action on dopaminergic receptors. By doing so, there drug not only treats the positive symptoms of schizophrenia but also the negative symptoms, unlike the typical antipsychotics. The most commonly prescribed atypical antipsychotics are risperidone, olanzapine, clozapine, aripiprazole, quetiapine, etc.

According to Teva, in the U.S., nearly 25% of the schizophrenic population were prescribed risperidone, 18% were prescribed olanzapine, 16% were prescribed aripiprazole, 11% were prescribed with paliperidone 8% were prescribed quetiapine, 6% were prescribed with clozapine, and 16% were prescribed other drugs.

Moreover, a study published in the Saudi Pharmaceutical Journal in December 2023 stated that Atypical antipsychotics were the most widely prescribed medication for schizophrenic patients in Saudi Arabia, accounting for ~59% of total prescriptions, and among them, Aripiprazole was the most common atypical antipsychotic.

Atypical antipsychotics have gained huge importance in recent times due to their high safety profile as compared to typical antipsychotics and are well tolerated by patients. A study published in the Schizophrenia Bulletin of the Journal of Psychoses and Related Disorders in May 2024 has stated that up to 3 quarters of patients with schizophrenia who are prescribed clozapine have reported that the drug is effective for them in controlling their symptoms.

This reflects the popularity of atypical antipsychotics in schizophrenia treatment their higher adoption rate and consequently their market dominance.

Geographical Analysis

Asia-Pacific region is expected to grow with the highest CAGR in the forecast period.

The Asia-Pacific schizophrenia drugs market is expected to significantly grow in the forecasted period owing to factors such as rising prevalence, increasing diagnosis & treatment rate, and approval of novel antipsychotic drugs.

For instance, in June 2024, Luye Pharma Group announced that China's National Medical Products Administration (NMPA) approved Meibirui for the acute and maintenance treatment of schizophrenia. Meibirui is the long-acting Paliperidone Palmitate Injection that can significantly improve the clinical outcome of a patient as compared to oral treatments.

However, in October 2024, Zai Lab Limited announced the positive results from phase 3 clinical trials of KarXT-a new generation antipsychotic drug for schizophrenia patients. Zai Lab possesses an exclusive license from Bristol Myers Squibb to develop, manufacture, and commercialize KarXT in Greater China. The approval is anticipated in 2025 which can address a significant proportion of the schizophrenia population in China.

Competitive Landscape

The major global players in the schizophrenia drugs market are Bristol-Myers Squibb Company, Otsuka Pharmaceutical Co., Ltd., CHEPLAPHARM Arzneimittel GmbH, Johnson & Johnson Services, Inc., Sumitomo Pharma Co., Ltd., Novartis AG, Tasman Pharma, INC., Intra-Cellular Therapies, Inc., AbbVie Inc., Alkermes, Inc., Viatris Inc. and Vanda Pharmaceuticals Inc. among others.

Emerging Players

The emerging players in the schizophrenia drugs market include Anavex Life Sciences Corp., Spinogenix, AbbVie Inc., Alto Neuroscience Inc., ATAI LIFE SCIENCES N.V., Reviva Pharmaceuticals Holdings, Inc., and Teva Pharmaceutical Industries Ltd. among others.

Key Developments

• In September 2024, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride) for the treatment of schizophrenia in adult patients. Cobenfy developed by Bristol Myers Squibb is the first drug approved after 35 years with a new mechanism of action targeting muscarinic M1 and M4 receptors in the brain without any antagonism on D2 receptors.
• In March 2024, the European Commission (EC) approved a long-acting injectable called Abilify Maintena 960mg (aripiprazole) for maintenance therapy among schizophrenia patients. Abilify Maintena developed by Otsuka Pharmaceutical Co., Ltd, and H. Lundbeck A/S is a once-every-two-months formulation and received its approval in all member countries of the European Union.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
• Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global melanoma therapeutics market report would provide approximately 54 tables, 46 figures, and 195 pages.

Target Audience 2023

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising prevalence of schizophrenia
    • 4.1.1.2. Rising demand for advanced therapeutics
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with the drugs
  • 4.1.3. Opportunities
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Epidemiology
• 5.3. Pricing Analysis
• 5.4. Pipeline Analysis
• 5.5. Patent Analysis
• 5.6. Regulatory Analysis

6. By Drug Class

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 6.1.2. Market Attractiveness Index, By Drug Class
• 6.2. Typical Antipsychotics*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Atypical Antipsychotics
  • 6.3.1. Quetiapine
  • 6.3.2. Aripiprazole
  • 6.3.3. Risperidone
  • 6.3.4. Lurasidone
  • 6.3.5. Clozapine
  • 6.3.6. Olanzapine
  • 6.3.7. Brexpiprazole
  • 6.3.8. Lumateperone
  • 6.3.9. Others

7. By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.1.2. Market Attractiveness Index, By Route of Administration
• 7.2. Oral*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Parenteral

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacies
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

Key Market Players

• 11.1. Bristol-Myers Squibb Company*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
    • 11.1.2.1. Product Description
    • 11.1.2.2. Product Key Performance Indicators (KPIs)
    • 11.1.2.3. Historic and Forecasted Product Sales
    • 11.1.2.4. Product Sales Volume
  • 11.1.3. Financial Overview
    • 11.1.3.1. Company Revenue's
    • 11.1.3.2. Geographical Revenue Shares
    • 11.1.3.3. Revenue Forecasts
  • 11.1.4. Key Developments
    • 11.1.4.1. Mergers & Acquisitions
    • 11.1.4.2. Key Product Development Activities
    • 11.1.4.3. Regulatory Approvals etc.
  • 11.1.5. SWOT Analysis
• 11.2. Otsuka Pharmaceutical Co., Ltd.
• 11.3. CHEPLAPHARM Arzneimittel GmbH
• 11.4. Johnson & Johnson Services, Inc.
• 11.5. Sumitomo Pharma Co., Ltd.
• 11.6. Novartis AG
• 11.7. Tasman Pharma, INC.
• 11.8. Intra-Cellular Therapies, Inc.
• 11.9. AbbVie Inc.
• 11.10. Alkermes, Inc.
• 11.11. Viatris Inc.
• 11.12. Vanda Pharmaceuticals Inc.
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us